

Global Orphan Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023

<https://marketpublishers.com/r/G815C58F4DBEN.html>

Date: September 2017

Pages: 125

Price: US\$ 2,750.00 (Single User License)

ID: G815C58F4DBEN

Abstracts

Orphan Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

Overview: Orphan diseases or rare diseases rarely occur among the people, which is nearly 7 out of 10,000 individuals. Around 5,000 to 8,000 rare diseases have been recognized and the origin of approximately 80% of these diseases is from the genes. Regardless of the alleged huge number of individuals being affected by rare life-threatening conditions, the disease burden estimates of the public health are unreliable. About 50% of the orphan genetic ailments are in kids' with 30% of them cannot live for more than 5 years.

New-born screening, legislation, and construction of national strategies are the major activities being carried out in the orphan drugs market. Legislation has helped in driving the development of more orphan drugs. For instance, the US congress passed Orphan Drug Act in 1983, and it was mainly intended to encourage development of new drugs for rare diseases. Currently, numerous legislation and strategies are developed to facilitate research of orphan drugs globally in more than 35 countries.

Cancer, metabolic diseases, blood diseases, immunologic disease, and neurologic diseases are the types of diseases that are addressed with orphan drugs. Cystic fibrosis, glioma, pancreatic cancer, acute myeloid leukemia, multiple myeloma, renal cell carcinoma, ovarian cancer and Duchenne muscular dystrophy are some of the common indications among the various disease types.

Market Analysis: The “Global Orphan Drugs Market” is estimated to witness a CAGR of 11.9% during the forecast period 2017–2023. The market is analyzed based on three

segments, namely types, applications, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the orphan drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India, China, and Japan are set to be the most attractive destinations due to the large untapped market.

Types Analysis: The global orphan drugs market by products is segmented into biologics and non-biologics. Biologics orphan drugs is the largest segment in the market with a market share of more than 60% in 2016. It is expected to grow at a double-digit CAGR in the market. However, non-biologic orphan drugs are still expected to hold more than quarter of the market share by 2023. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the global orphan drugs market.

Key Players: Novartis AG, F. Hoffmann-La Roche Ltd, Celgene, Bristol-Myers Squibb Company, Shire pharmaceuticals, Pfizer, Sonafi, and Bayer Healthcare are the key players in the market. These top ten players occupy nearly 50% of the orphan drugs market.

Competitive Analysis: Currently, large pharmaceutical companies are extremely active in the orphan drugs market. Merger and acquisition is the major trend in the market. For instance, around 40% of the biotechnology companies are acquired between the year 2008-2012, and they have an orphan drug in development. Novartis, GSK, Roche, and Pfizer are the largest orphan drug companies. Pfizer, Gilead, Roche, Shire, BMY, and Celgene are leading orphan drug acquirers. Around 50% of the top 20 orphan drugs were either acquired or in-licensed by large pharmaceutical companies.

Benefits: The report provides complete details about the usage and adoption rate of orphan drugs during the forecast period and among the regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the orphan drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
- 1.2 Industry Trends

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Segmented Addressable Market (SAM)
 - 3.2.1 Advantages of Development of Orphan Drug
 - 3.2.2 Trends of orphan drug market
- 3.3 Related Addressable Markets (RAM)
 - 3.3.1 Oncology (Cancer) Drugs
 - 3.3.2 Active pharmaceutical ingredients (APIs)
 - 3.3.3 Over the counter drugs (OTC)

4 MARKET OUTLOOK

- 4.1 Overview
- 4.2 Regulatory Framework for orphan drugs
- 4.3 Funding Scenario for orphan drugs
- 4.4 Market Segmentation
- 4.5 Porter 5(Five) Forces
- 4.6 PEST Analysis

5 MARKET CHARACTERISTICS

- 5.1 Market Dynamics
 - 5.1.1 Drivers
 - 5.1.1.1 Conducive government legislation

- 5.1.1.2 Marketing exclusivity for orphan drugs
- 5.1.1.3 Growing unmet need for treatment of orphan diseases
- 5.1.2 Opportunities
 - 5.1.2.1 Growing Novel indications for known orphan drugs
 - 5.1.2.2 Untapped emerging market
- 5.1.3 Restraints
 - 5.1.3.1 High cost of treatment
 - 5.1.3.2 Lack of Adequate patients for clinical trials
- 5.1.4 DRO – Impact Analysis
- 5.1.5 Key Stakeholders

6 DRUG DETAILS: MARKET SIZE AND ANALYSIS

- 6.1 Overview

7 TYPES: MARKET SIZE AND ANALYSIS

- 7.1 Overview
 - 7.1.1 Biologics
 - 7.1.2 Non-Biologics

8 APPLICATION: MARKET SIZE AND ANALYSIS

- 8.1 Overview
 - 8.1.1 Oncology
 - 8.1.2 Metabolic Diseases
 - 8.1.3 Hematology
 - 8.1.4 Infectious Diseases
 - 8.1.5 Neurology
 - 8.1.6 Others

9 PIPELINE MOLECULES: MARKET SIZE AND ANALYSIS

- 9.1 Overview

10 REGIONS: MARKET SIZE AND ANALYSIS

- 10.1 Overview
- 10.2 North America

- 10.2.1 Overview
- 10.2.2 US
- 10.2.3 Canada
- 10.3 Europe
 - 10.3.1 Overview
 - 10.3.1.1 UK
 - 10.3.1.2 Germany
 - 10.3.1.3 France
- 10.4 APAC
 - 10.4.1 Overview
 - 10.4.1.1 India
 - 10.4.1.2 Japan
 - 10.4.1.3 China
- 10.5 Rest of the World
 - 10.5.1 Overview
 - 10.5.1.1 Brazil
 - 10.5.1.2 Mexico
 - 10.5.1.3 Africa
 - 10.5.1.4 Middle East

11 COMPETITIVE LANDSCAPE

12 VENDOR PROFILES

- 12.1 Novartis AG
 - 12.1.1 Overview
 - 12.1.2 Business Unit
 - 12.1.3 Geographic Presence
 - 12.1.4 Business Focus
 - 12.1.5 SWOT Analysis
 - 12.1.6 Business Strategy
- 12.2 F.Hoffmann-La Roche Ltd
 - 12.2.1 Overview
 - 12.2.2 Business Unit
 - 12.2.3 Geographic Presence
 - 12.2.4 Business Focus
 - 12.2.5 SWOT Analysis
 - 12.2.6 Business Strategy
- 12.3 Celgene Corporation

- 12.3.1 Overview
- 12.3.2 Geographic Presence
- 12.3.3 Business Focus
- 12.3.4 SWOT Analysis
- 12.3.5 Business Strategy
- 12.4 Bristol-Myers Squibb
 - 12.4.1 Overview
 - 12.4.2 Geographic Presence
 - 12.4.3 Business Focus
 - 12.4.4 SWOT Analysis
 - 12.4.5 Business Strategy
- 12.5 Shire PLC
 - 12.5.1 Overview
 - 12.5.2 Business Unit
 - 12.5.3 Geographic Presence
 - 12.5.4 Business Focus
 - 12.5.5 SWOT Analysis
 - 12.5.6 Business Strategy

13 COMPANIES TO WATCH FOR

- 13.1 Pfizer Inc.,
 - 13.1.1 Overview
 - 13.1.2 Highlights
 - 13.2 Sanofi
 - 13.2.1 Overview
 - 13.3 Bayer AG
 - 13.3.1 Overview
 - 13.4 Alexion Pharmaceutical Inc.
 - 13.4.1 Overview
 - 13.5 Biogen Pharmaceuticals.
 - 13.5.1 Overview
 - 13.6 Eli Lilly and Company.
 - 13.6.1 Overview
 - 13.7 Amgen Inc.
 - 13.7.1 Overview
- Annexure
- Abbreviations

Tables

- Table 1 REGULATORY FRAMEWORK FOR ORPHAN DRUGS
- Table 2 FUNDED PROJECTS OF 2017
- Table 3 LIST OF ORPHAN DRUGS APPROVED IN THE MARKET
- Table 4 MARKET REVENUE OF TOP 15 DRUGS, 2016 AND 2023 (\$BILLION)
- Table 5 MOLECULES IN DEVELOPMENT (2015)
- Table 6 AUTOIMMUNE DISEASES MOLECULES
- Table 7 BLOOD DISORDER MOLECULES
- Table 8 RARE CANCER MOLECULES
- Table 9 BLOOD CANCER MOLECULES
- Table 10 CARDIOVASCULAR DISORDERS MOLECULES
- Table 11 DIGESTIVE DISORDERS MOLECULES
- Table 12 EYE DISORDERS MOLECULES
- Table 13 GENETIC DISORDERS MOLECULES
- Table 14 GROWTH DISORDERS MOLECULES
- Table 15 INFECTIOUS DISORDERS MOLECULES
- Table 16 NEUROLOGIC DISORDERS MOLECULES
- Table 17 RESPIRATORY DISORDERS MOLECULES
- Table 18 TRANSPLANTATION MOLECULES
- Table 19 OTHER DISORDERS MOLECULES IN THE PIPELINE
- Table 20 ORPHAN DRUGS MARKET REVENUE BY REGIONS, 2016–2023 (\$BILLION)
- Table 21 TOP 5 ORPHAN DRUGS IN THE US MARKET
- Table 22 REGULATORY AUTHORITIES IN ASIA PACIFIC
- Table 23 NOVARTIS AG: OFFERINGS
- Table 24 NOVARTIS AG: RECENT DEVELOPMENTS
- Table 25 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS
- Table 26 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
- Table 27 CELGENE CORPORATION: OFFERINGS
- Table 28 CELGENE CORPORATION: RECENT DEVELOPMENTS
- Table 29 BRISTOL–MYERS SQUIBB: OFFERINGS
- Table 30 BRISTOL–MYERS SQUIBB: RECENT DEVELOPMENTS
- Table 31 SHIRE PLC: OFFERINGS
- Table 32 SHIRE PLC: RECENT DEVELOPMENTS
- Table 33 PFIZER: RECENT DEVELOPMENTS
- Table 34 SANOFI: RECENT DEVELOPMENTS
- Table 35 BAYER AG: RECENT DEVELOPMENTS
- Table 36 ALEXION PHARMACEUTICAL, INC.: RECENT DEVELOPMENTS
- Table 37 BIOGEN PHARMACEUTICALS: RECENT DEVELOPMENTS

Table 38 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS

Table 39 AMGEN INC.: RECENT DEVELOPMENTS

Charts

Chart 1 PEST ANALYSIS OF ORPHAN DRUGS MARKET

Chart 2 RESEARCH METHODOLOGY OF GLOBAL ORPHAN DRUGS MARKET

Chart 3 GLOBAL ORPHAN DRUGS MARKET REVENUE, 2016–2023 (\$BILLION)

Chart 4 SEGMENTATION OF GLOBAL ORPHAN DRUGS MARKET

Chart 5 PORTER 5 FORCES OF ORPHAN DRUGS MARKET

Chart 6 MARKET DYNAMICS – DRO ANALYSIS

Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL ORPHAN DRUGS MARKET

Chart 8 KEY STAKEHOLDERS OF GLOBAL ORPHAN DRUGS MARKET

Chart 9 ORPHAN DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 VS. 2023 (\$BILLION)

Chart 10 BIOLOGICS ORPHAN DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016–2023 (\$BILLION)

Chart 11 NON-BIOLOGICS ORPHAN DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016–2023 (\$BILLION)

Chart 12 ORPHAN DRUGS MARKET SHARE BY APPLICATION SEGMENTATION, 2016 (%)

Chart 13 HEMATOLOGY MARKET SHARE, 2016

Chart 14 ORPHAN DRUG THERAPEUTIC AREA IN PIPELINE, 2016

Chart 15 ORPHAN DRUGS IN PIPELINE, 2016

Chart 16 ORPHAN DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2016 VS. 2023 (%)

Chart 17 ORPHAN DRUGS MARKET REVENUE IN NORTH AMERICA, 2016–2023 (\$BILLION)

Chart 18 ORPHAN DRUGS MARKET REVENUE IN EUROPE, 2016–2023 (\$BILLION)

Chart 19 ORPHAN DRUGS MARKET REVENUE IN APAC, 2016–2023 (\$BILLION)

Chart 20 ORPHAN DRUGS MARKET REVENUE IN REST OF THE WORLD, 2016–2023 (\$BILLION)

Chart 21 ORPHAN DRUGS MARKET SHARE, 2016

Chart 22 NOVARTIS AG: OVERVIEW SNAPSHOT

Chart 23 NOVARTIS AG: BUSINESS UNITS

Chart 24 NOVARTIS AG: GEOGRAPHIC REVENUE

Chart 25 NOVARTIS AG: SWOT ANALYSIS

Chart 26 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT

Chart 27 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS

Chart 28 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE

Chart 29 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 30 CELGENE CORPORATION: OVERVIEW SNAPSHOT
Chart 31 CELGENE CORPORATION: GEOGRAPHIC REVENUE
Chart 32 CELGENE CORPORATION: SWOT ANALYSIS
Chart 33 BRISTOL–MYERS SQUIBB: OVERVIEW SNAPSHOT
Chart 34 BRISTOL–MYERS SQUIBB: BUSINESS SEGMENTS
Chart 35 BRISTOL–MYERS SQUIBB: GEOGRAPHIC REVENUE
Chart 36 BRISTOL–MYERS SQUIBB: SWOT ANALYSIS
Chart 37 SHIRE PLC: OVERVIEW SNAPSHOT
Chart 38 SHIRE PLC: BUSINESS UNITS
Chart 39 SHIRE PLC: GEOGRAPHIC REVENUE
Chart 40 SHIRE PLC: SWOT ANALYSIS

I would like to order

Product name: Global Orphan Drugs Market Trends and Drivers, Restraints, and Opportunities
2017-2023

Product link: <https://marketpublishers.com/r/G815C58F4DBEN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/G815C58F4DBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970

